{"id":74978,"date":"2026-08-17T13:24:38","date_gmt":"2026-08-17T05:24:38","guid":{"rendered":"https:\/\/flcube.com\/?p=74978"},"modified":"2026-08-17T13:24:39","modified_gmt":"2026-08-17T05:24:39","slug":"henlius-and-sandoz-strike-strategic-biosimilars-deal-covering-up-to-10-mab-and-adc-products-worth-usd-314-million-for-initial-assets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=74978","title":{"rendered":"Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets"},"content":{"rendered":"\n

Shanghai Henlius Biotech, Inc.<\/strong> (HKG: 2696<\/a>) announced that it has entered into a strategic collaboration with Sandoz<\/strong> (SWX: SDZ<\/a>), covering up to 10 proposed monoclonal antibody (mAb) and\/or antibody\u2011drug conjugate (ADC) biosimilar products or components<\/strong> developed by Henlius. The parties have also signed collaboration terms for an initial three agreed products<\/strong> and an option for one additional asset<\/strong>, further deepening the existing oncology biosimilars collaboration between the two companies.<\/p>\n\n\n\n

Deal Structure<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Parties<\/strong><\/td>Shanghai Henlius Biotech (HKG: 2696) and Sandoz (SWX: SDZ)<\/td><\/tr>
Scope<\/strong><\/td>Up to 10 proposed mAb and\/or ADC biosimilar products or components<\/td><\/tr>
Initial Products<\/strong><\/td>Three agreed assets, plus an option on one additional asset<\/td><\/tr>
Rights Granted<\/strong><\/td>Exclusive registration and commercialization rights outside China, up to worldwide<\/td><\/tr>
Collaboration Model<\/strong><\/td>Multi\u2011product portfolio framework spanning development, regulatory submissions, manufacturing, launch, commercialization, and lifecycle management<\/td><\/tr>
Prior Relationship<\/strong><\/td>April 2025 exclusive commercialization partnership for HLX13 (ipilimumab biosimilar) across 46 countries and regions, including Europe and the US<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Initial Assets & Territories<\/h2>\n\n\n\n
Asset<\/th>Proposed Biosimilar Of<\/th>Exclusive Territory<\/th><\/tr><\/thead>
HLX05\u2011N<\/strong><\/td>Cetuximab<\/td>US, Canada, EU and certain other European countries including UK and Switzerland, Japan, Australia and New Zealand; semi\u2011exclusive rights in certain Asian countries\/regions and other markets<\/td><\/tr>
HLX16<\/strong><\/td>Evolocumab<\/td>All markets worldwide outside China<\/td><\/tr>
Belimumab biosimilar<\/strong><\/td>Belimumab<\/td>All markets worldwide outside China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Most of the partnered products are currently at early stages of development, and the two parties will collaborate closely from the earliest stages of project development.<\/p>\n\n\n\n

Financial Terms<\/h2>\n\n\n\n
Component<\/th>Value (USD)<\/th><\/tr><\/thead>
Upfront Payment<\/strong><\/td>Up to 77 million<\/strong><\/td><\/tr>
Development Milestones & Development Budget Milestones<\/strong><\/td>Up to 160 million<\/strong><\/td><\/tr>
Sales Milestones<\/strong><\/td>Up to 77 million<\/strong><\/td><\/tr>
Total for Initial Three Products<\/strong><\/td>Up to 314 million<\/strong><\/td><\/tr>
Royalties<\/strong><\/td>Tiered royalties on net sales<\/td><\/tr>
Option Fee (HLXTE\u2011HAase1001)<\/strong><\/td>Non\u2011refundable 8 million<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

In addition, Sandoz<\/strong> has obtained an option for HLXTE\u2011HAase1001<\/strong>, a recombinant human hyaluronidase, for a non\u2011refundable option fee of USD 8 million<\/strong>. If Sandoz exercises the option, the parties will enter into separate definitive agreements covering that product.<\/p>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n